temozolomide has been researched along with mln 8237 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnett, KD; Brown, SL; deCarvalho, AC; Ecsedy, JA; Hong, X; Lehman, NL; Mikkelsen, T; O'Donnell, JP; Pearl, DK; Salazar, CR; Van Brocklyn, JR | 1 |
Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L | 1 |
Chen, Y; Dong, B; Guo, B; Liang, Y; Qiao, W; Xu, W; Zhou, H | 1 |
1 trial(s) available for temozolomide and mln 8237
Article | Year |
---|---|
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Camptothecin; Child; Child, Preschool; Dacarbazine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Genotype; Glucuronosyltransferase; Humans; Infant; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neuroblastoma; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Tablets; Temozolomide; Time Factors; Treatment Outcome; United States; Young Adult | 2016 |
2 other study(ies) available for temozolomide and mln 8237
Article | Year |
---|---|
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation.
Topics: Apoptosis; Azepines; Cell Proliferation; Dacarbazine; Glioblastoma; Humans; Protein Kinase Inhibitors; Pyrimidines; Radiation, Ionizing; Temozolomide | 2014 |
miR-124 suppresses glioblastoma growth and potentiates chemosensitivity by inhibiting AURKA.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Base Sequence; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sequence Homology, Nucleic Acid; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |